A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes
| Condition | Type 2 Diabetes Mellitus |
|---|---|
| Phase | Phase 3 |
| Sponsor | Eli Lilly and Company |
| Status | Completed |
| Enrollment | 13,299 participants |
| Interventions | Tirzepatide, Dulaglutide |
| Start date | May 29, 2020 |
| Completion date | Jun 12, 2025 |
| Results posted | Jul 8, 2026 |
Summary
The purpose of the trial is to assess the efficacy and safety of tirzepatide to dulaglutide in participants with type 2 diabetes and increased cardiovascular risk.
Number of Participants From Randomization to First Occurrence of Death From MACE-3 [Composite Endpoint of Major Adverse Cardiovascular Events Death From Cardiovascular Causes, Myocardial Infarction (MI) or Stroke]
| Tirzepatide (MTD) | 801 participants |
|---|---|
| 1.5 mg Dulaglutide | 862 participants |
Open in BENITIONS View on ClinicalTrials.gov
Other trials for this condition
- Cardiovascular Outcomes in Bariatric Surgery Patients With Type 2 Diabetes — The Cleveland Clinic
- Diabetes Prevention Program Outcomes Study — National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Uric Acid Lowering Trial in Youth Onset T2D — University of Colorado, Denver
- Financial Incentives And Nurse Coaching to Enhance Diabetes Outcomes (FINANCE-DM)-1 — State University of New York at Buffalo
- Continuous Glucose Monitoring Following Hospital Discharge — Kathleen Dungan
- Skeletal Muscle Diacylglycerol and Sphingolipids - Impact of Localization and Species on I — University of Colorado, Denver